AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8813788 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose preoperative radiotherapy (5 x 5 Gy)
Number of subjects: 1399
Study 8813788 — intervention group
Group type: COMPARATOR
Intervention: No preoperative radiotherapy
Number of subjects: 1399
Study 8813788 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-portal technique to a limited volume
Number of subjects: 1399
Study 1551634 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon-alpha (5 million U/m2, three times a week for 6 months)
Number of subjects: 60
Study 1551634 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 60
Study 1551634 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon-alpha
Number of subjects: 60
Study 2860044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 633
Study 31025930 — intervention group
Group type: EXPERIMENTAL
Intervention: tocilizumab 8 mg/kg intravenously at study begin and weeks 4, 8, and 12
Number of subjects: 519
Study 31025930 — intervention group
Group type: COMPARATOR
Intervention: rituximab 1000 mg at weeks 16 and 18
Number of subjects: 519
Study 30334433 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Probiotics
Number of subjects: 0
Study 27155493 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 plus trivalent inactivated influenza vaccine
Number of subjects: 1116
Study 27155493 — intervention group
Group type: EXPERIMENTAL
Intervention: Revaccination with PCV13
Number of subjects: 1116
Study 27155493 — intervention group
Group type: COMPARATOR
Intervention: Initial vaccination with PCV13
Number of subjects: 1116
Study 23528191 — intervention group
Group type: EXPERIMENTAL
Intervention: Religiosity assessed before alcohol consumption questions
Number of subjects: 301
Study 23528191 — intervention group
Group type: COMPARATOR
Intervention: Religiosity assessed after alcohol consumption questions
Number of subjects: 301
Study 22330975 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (open reduction and internal fixation)
Number of subjects: 81
Study 22330975 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment (short leg cast or brace and protected weight bearing for 6 weeks)
Number of subjects: 81
Study 21164552 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive video game stationary cycling (GameBike)
Number of subjects: 30
Study 21164552 — intervention group
Group type: COMPARATOR
Intervention: Stationary cycling to music
Number of subjects: 30
Study 21164552 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 30
Study 18044288 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental 5 mg/kg
Number of subjects: 120
Study 18044288 — intervention group
Group type: COMPARATOR
Intervention: Propofol 2 mg/kg
Number of subjects: 120
Study 16248728 — intervention group
Group type: EXPERIMENTAL
Intervention: Causal judgment task with revaluation of cue A (A+ and A-)
Number of subjects: 0
Study 16248728 — intervention group
Group type: EXPERIMENTAL
Intervention: Within-compound associations
Number of subjects: 0
Study 11790236 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose creatine (150 mg/kg daily)
Number of subjects: 19
Study 11790236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 10628186 — intervention group
Group type: EXPERIMENTAL
Intervention: Provitamin A carotenoids in dark green, leafy vegetables (DGLV)
Number of subjects: 0
Study 10628186 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure chemical beta-carotene
Number of subjects: 0
Study 10628186 — intervention group
Group type: COMPARATOR
Intervention: Low vitamin A fare
Number of subjects: 0
Study 8720287 — intervention group
Group type: COMPARATOR
Intervention: Ribavirin alone (15 mg/kg daily for 6 months)
Number of subjects: 45
Study 8720287 — intervention group
Group type: COMPARATOR
Intervention: Interferon alone (3 MU thrice weekly for 6 months)
Number of subjects: 45
Study 8720287 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon plus ribavirin (at above doses)
Number of subjects: 45
Study 1451730 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.07 mg digitoxin o.d. for up to 58 days
Number of subjects: 12
Study 1451730 — intervention group
Group type: COMPARATOR
Intervention: 25 mg oral captopril b.d. (concomitant administration)
Number of subjects: 12
Study 6331480 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 9
Study 6331480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 6331480 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril + Naloxone
Number of subjects: 9
Study 31201177 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based coaching for patients experiencing depression, anxiety, or at-risk drinking
Number of subjects: 23
Study 31201177 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert psychiatric recommendations
Number of subjects: 23
Study 31201177 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational adoption and implementation of the study
Number of subjects: 23
Study 29128648 — intervention group
Group type: EXPERIMENTAL
Intervention: ED-initiated Screening, Brief Intervention, and Referral for Treatment (SBIRT) focused on HTN
Number of subjects: 0
Study 29128648 — intervention group
Group type: EXPERIMENTAL
Intervention: ED-initiated SBIRT coupled with a Post-Acute Care Hypertension Transition Consultation by ED Clinical Pharmacists
Number of subjects: 0
Study 29128648 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 26179360 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec and insulin degludec/insulin aspart
Number of subjects: 536
Study 26179360 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal‐oral therapy
Number of subjects: 536
Study 26179360 — intervention group
Group type: COMPARATOR
Intervention: Type 1 diabetes
Number of subjects: 536
Study 26179360 — intervention group
Group type: COMPARATOR
Intervention: Type 2 diabetes multiple daily injections
Number of subjects: 536
Study 25294380 — intervention group
Group type: EXPERIMENTAL
Intervention: Diarrhea-predominant IBS (D-IBS) patients
Number of subjects: 62
Study 22471899 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fucidic acid plus betamethasone valerate cream
Number of subjects: 25
Study 22471899 — intervention group
Group type: COMPARATOR
Intervention: Topical fucidic acid (control group)
Number of subjects: 25
Study 19963314 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a nautical inclinometer and a plastic, double-equilateral triangle with an 8-cm-long border for positioning and port placement during RALP
Number of subjects: 0
Study 17915970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (40-160 mg/day)
Number of subjects: 62
Study 17915970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 62
Study 17915970 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 62
Study 15610070 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (500 mg orally 2 hours before ischaemia)
Number of subjects: 13
Study 15610070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 15610070 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 13
Study 12392582 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous midazolam (0.1 mg kg‐1)
Number of subjects: 18
Study 12392582 — intervention group
Group type: COMPARATOR
Intervention: Intravenous midazolam (0.1 mg kg‐1)
Number of subjects: 18
Study 10427921 — intervention group
Group type: EXPERIMENTAL
Intervention: HEMA IOL (Hydroview)
Number of subjects: 232
Study 7493374 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I-labeled hMN-14 IgG (8 to 30 mCi, 0.5 to 20.0 mg)
Number of subjects: 19
Study 7493374 — intervention group
Group type: COMPARATOR
Intervention: 131I-labeled mMN-14 IgG
Number of subjects: 19
Study 7493374 — intervention group
Group type: EXPERIMENTAL
Intervention: hMN-14 (3 injections)
Number of subjects: 19
Study 7493374 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor radiation absorbed dose
Number of subjects: 19
Study 2372154 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg buprenorphine every 6 h for 36 h
Number of subjects: 50
Study 2372154 — intervention group
Group type: COMPARATOR
Intervention: 10 mg morphine every 6 h for 36 h
Number of subjects: 50
Study 6765526 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin (recombinant DNA)
Number of subjects: 131
Study 6765526 — intervention group
Group type: COMPARATOR
Intervention: Purified pork insulin preparation (regular and NPH insulin)
Number of subjects: 131
Study 6765526 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 131
Study 6765526 — intervention group
Group type: COMPARATOR
Intervention: Purified beef insulin (regular and NPH insulin)
Number of subjects: 131
Study 30844611 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Number of subjects: 2376
Study 30844611 — intervention group
Group type: COMPARATOR
Intervention: IFN β‐1a
Number of subjects: 2376
Study 30844611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2376
Study 29911875 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive interaction
Number of subjects: 220
Study 29911875 — intervention group
Group type: COMPARATOR
Intervention: Noncompetitive interaction
Number of subjects: 220
Study 29231294 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at Neiguan (PC 6) combined with press needles
Number of subjects: 120
Study 29231294 — intervention group
Group type: COMPARATOR
Intervention: Acupressure at Neiguan (PC 6)
Number of subjects: 120
Study 25654959 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (LFX) 500 mg o.d. with scaling and root planing (SRP)
Number of subjects: 69
Study 25654959 — intervention group
Group type: COMPARATOR
Intervention: Placebo with scaling and root planing (SRP)
Number of subjects: 69
Study 21672162 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal dressing applied after scaling and root planning (SRP)
Number of subjects: 30
Study 21672162 — intervention group
Group type: COMPARATOR
Intervention: No periodontal dressing (Control group)
Number of subjects: 30
Study 19106241 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fat and saturated fat intake
Number of subjects: 532
Study 19106241 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower carbohydrate intake
Number of subjects: 532
Study 19106241 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher insulin dose
Number of subjects: 532
Study 19106241 — intervention group
Group type: EXPERIMENTAL
Intervention: Substitution of fat for carbohydrate
Number of subjects: 532
Study 17454224 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (20g/500 mL intravenously daily for 5 days followed by 4 g/day orally for 2 weeks)
Number of subjects: 74
Study 17454224 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 74
Study 17454224 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 74
Study 15253854 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes to Alternative Medicine Scale (pre-proving)
Number of subjects: 206
Study 15253854 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes to Alternative Medicine Scale (post-proving)
Number of subjects: 206
Study 11238428 — intervention group
Group type: EXPERIMENTAL
Intervention: Information, education and communication activities (IEC)
Number of subjects: 36
Study 11238428 — intervention group
Group type: EXPERIMENTAL
Intervention: IEC interventions with improved treatment of STDs
Number of subjects: 36
Study 11238428 — intervention group
Group type: COMPARATOR
Intervention: Community development activities unrelated to HIV
Number of subjects: 36
Study 9678725 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescreening of Pap smear slides
Number of subjects: 0
Study 8202905 — intervention group
Group type: COMPARATOR
Intervention: Chinese
Number of subjects: 2868
Study 8202905 — intervention group
Group type: EXPERIMENTAL
Intervention: Malays
Number of subjects: 2868
Study 8202905 — intervention group
Group type: EXPERIMENTAL
Intervention: Indians
Number of subjects: 2868
Study 2660551 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 2 g B.I.D.
Number of subjects: 54
Study 2660551 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Sucralfate H.S.
Number of subjects: 54
Study 2660551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 30919704 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to 15, 25, and 46 ng/m3 Der p1
Number of subjects: 24
Study 30919704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30919704 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 31169045 — intervention group
Group type: EXPERIMENTAL
Intervention: Microswitch intervention
Number of subjects: 6
Study 28537325 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Protein (TP) intake
Number of subjects: 554
Study 28537325 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal Protein (AP) intake
Number of subjects: 554
Study 28537325 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant Protein (PP) intake
Number of subjects: 554
Study 28537325 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium 1000 mg/d and cholecalciferol 800 IU for 3 years (intervention group)
Number of subjects: 554
Study 28537325 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 554
Study 28537325 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Protein (TP) intake in active women
Number of subjects: 554
Study 25482425 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg FXI‐ASO
Number of subjects: 300
Study 25482425 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg FXI‐ASO
Number of subjects: 300
Study 25482425 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (40 mg once daily)
Number of subjects: 300
Study 23692550 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration Training Group (WBVTG), n=26, undergoing three sessions per week for a total of 6 weeks
Number of subjects: 60
Study 23692550 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG), n=25, without intervention
Number of subjects: 60
Study 21714890 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated juice powder concentrates (with added berry powders)
Number of subjects: 64
Study 21714890 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated juice powder concentrates (without added berry powders)
Number of subjects: 64
Study 21714890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 21714890 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated juice powder concentrates (with and without added berry powders)
Number of subjects: 64
Study 19366271 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan/HCTZ 32/25 mg
Number of subjects: 1524
Study 19366271 — intervention group
Group type: COMPARATOR
Intervention: Candesartan 32 mg
Number of subjects: 1524
Study 19366271 — intervention group
Group type: COMPARATOR
Intervention: HCTZ 25 mg
Number of subjects: 1524
Study 19366271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1524
Study 16712531 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation attempted by paramedics without appropriate drugs to facilitate intubation.
Number of subjects: 0
Study 16712531 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation facilitated by sedative drugs (but not relaxant drugs).
Number of subjects: 0
Study 16712531 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid sequence intubation for comatose patients transported by helicopter.
Number of subjects: 0
Study 16712531 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of waveform capnography in intubated head injury patients.
Number of subjects: 0
Study 16712531 — intervention group
Group type: COMPARATOR
Intervention: Rapid transport to hospital without intubation for road-based paramedics.
Number of subjects: 0
Study 14625264 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g of alcohol per day
Number of subjects: 53
Study 14625264 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g of alcohol per day
Number of subjects: 53
Study 11046203 — intervention group
Group type: EXPERIMENTAL
Intervention: Hetastarch (15 ml/kg, 6%)
Number of subjects: 11
Study 11046203 — intervention group
Group type: COMPARATOR
Intervention: Albumin (15 ml/kg, 5%)
Number of subjects: 11
Study 9277655 — intervention group
Group type: EXPERIMENTAL
Intervention: Gasless laparoscopy
Number of subjects: 57
Study 9277655 — intervention group
Group type: COMPARATOR
Intervention: Pneumoperitoneum
Number of subjects: 57
Study 8370687 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (APD) 30 mg, iv, daily for 2 days
Number of subjects: 22
Study 8370687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 2942116 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol
Number of subjects: 138
Study 2942116 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol and ipratropium (combined treatment)
Number of subjects: 138
Study 2942116 — intervention group
Group type: COMPARATOR
Intervention: Nebulised doses (both treatments)
Number of subjects: 138
Study 29080906 — intervention group
Group type: EXPERIMENTAL
Intervention: mCPP (30mg)
Number of subjects: 0
Study 29080906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27663694 — intervention group
Group type: EXPERIMENTAL
Intervention: Mainstream mask capnography system (cap‐ONE)
Number of subjects: 39
Study 27663694 — intervention group
Group type: COMPARATOR
Intervention: Side stream sampling nasal cannula capnography (NC)
Number of subjects: 39
Study 24820639 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian method based on subgroup analysis
Number of subjects: 0
Study 24820639 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian method based on regression model
Number of subjects: 0
Study 24820639 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression-based method
Number of subjects: 0
Study 22808932 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based yoga program
Number of subjects: 98
Study 22808932 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based yoga program (good adherence)
Number of subjects: 98
Study 22808932 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98
Study 20180613 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (sertraline or citalopram) with or without cognitive behavioral therapy
Number of subjects: 0
Study 20180613 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacologic therapy (aerobic exercise)
Number of subjects: 0
Study 20180613 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for depression
Number of subjects: 0
Study 18351428 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher testosterone levels
Number of subjects: 445
Study 18351428 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher testosterone levels with vitamin D plus calcium supplementation
Number of subjects: 445
Study 18351428 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher DHEA-S levels (in women)
Number of subjects: 445
Study 15972618 — intervention group
Group type: EXPERIMENTAL
Intervention: G80 (80% 1RM)
Number of subjects: 112
Study 15972618 — intervention group
Group type: EXPERIMENTAL
Intervention: G50 (50% 1RM)
Number of subjects: 112
Study 15972618 — intervention group
Group type: EXPERIMENTAL
Intervention: G20 (20% 1RM)
Number of subjects: 112
Study 15972618 — intervention group
Group type: COMPARATOR
Intervention: CON (nontraining control group)
Number of subjects: 112
Study 12923507 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral sagittal split osteotomy
Number of subjects: 93
Study 10229886 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid fixation
Number of subjects: 117
Study 10229886 — intervention group
Group type: COMPARATOR
Intervention: Wire fixation
Number of subjects: 117
Study 10229886 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Rigid and Wire fixation)
Number of subjects: 117
Study 8561153 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day course of 20 mg omeprazole b.i.d. orally combined with 2 g amoxicillin t.i.d. intravenously for 1 day (n=10)
Number of subjects: 40
Study 8561153 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day course of 20 mg omeprazole b.i.d. orally combined with 2 g amoxicillin t.i.d. intravenously for 3 days (n=10)
Number of subjects: 40
Study 8561153 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day course of 20 mg omeprazole b.i.d. orally combined with 2 g amoxicillin t.i.d. intravenously for 5 days (n=10)
Number of subjects: 40
Study 8561153 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day course of 20 mg omeprazole b.i.d. orally combined with 2 g amoxicillin t.i.d. intravenously for 7 days (n=10)
Number of subjects: 40
Study 1888322 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment (for treated phobics)
Number of subjects: 57
Study 1888322 — intervention group
Group type: COMPARATOR
Intervention: No treatment (for untreated phobics)
Number of subjects: 57
Study 1888322 — intervention group
Group type: COMPARATOR
Intervention: No treatment (for no-fear controls)
Number of subjects: 57
Study 7036285 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG immunotherapy
Number of subjects: 52
Study 7036285 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG plus allogeneic tumor cells
Number of subjects: 52
Study 7036285 — intervention group
Group type: COMPARATOR
Intervention: No further therapy (Control)
Number of subjects: 52
Study 7036285 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (combined BCG arms)
Number of subjects: 52
Study 31568890 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical nerve stimulation (ENS)
Number of subjects: 52
Study 31568890 — intervention group
Group type: COMPARATOR
Intervention: Conventional loco-regional anesthesia (Local group)
Number of subjects: 52
Study 30596511 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical Simple Stitch (SS)
Number of subjects: 86
Study 30596511 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Mason-Allen Stitch (BRUMA)
Number of subjects: 86
Study 28043903 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (40 mg daily)
Number of subjects: 1092